Cisplatin, ifosfamide, oral etoposide, and concurrent accelerated hyperfractionated thoracic radiation for patients with limited small-cell lung carcinoma: Results of radiation therapy oncology group trial 93-12

Journal of Clinical Oncology

Volumn 18, Issue 16, 2000, Pages 2990-2995

  Glisson, Bonnie ^a   Scott, Charles ^a   Komaki, Ritsuko ^a   Movsas, Benjamin ^a   Wagner, Henry ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE; IFOSFAMIDE;

ADULT; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; ESOPHAGITIS; FEMALE; FEVER; GRANULOCYTOPENIA; HUMAN; INFECTION; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0033901542     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.16.2990     Document Type: Article

References (26)

1. A meta-analysis of thoracic radiotherapy for small-cell lung cancer
2. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis
3. Final results of a phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small cell lung cancer: The Japan Clinical Oncology Group Study
4. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer
5. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: A randomized study
6. Concurrent chemotherapy/radiotherapy for limited small-cell lung carcinoma: A Southwest Oncology Group Study
7. A preliminary report: Concurrent twice-daily radiotherapy plus platinum-etoposide chemotherapy for limited small cell lung cancer
8. Patients with limited-stage small-cell lung cancer treated with concurrent twice,daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine
9. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide
10. Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma
11. Integration of filgrastim into chemoradiation for limited small cell lung cancer: A phase I study
12. Reporting results of cancer treatment
13. Non-parametric estimation from incomplete observations
14. Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: An Eastern Cooperative Oncology Group pilot study
15. Etoposide, ifosfamide and cisplatin in extensive small celt lung cancer
16. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: A Hoosier Oncology Group study
17. Schedule dependence of the antileukaemic activity of the podophyllotoxin-derivative VP 16-213 (NSC 141540) in L1210 leukaemia
18. Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: A phase II trial
19. Phase II trial of daily oral VP-16 in refractory small cell lung cancer: A Hoosier Oncology Group study
20. Prolonged administration of single-agent oral etoposide in patients with untreated small cell lung cancer (SCLC)
21. A phase II trial of cisplatin and prolonged administration of oral etoposide in extensive-stage small cell lung cancer
22. Schedule dependence of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive stage small-cell lung cancer: A randomized phase Ill study of the Cancer and Leukemia Group B
23. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell lung cancer: Radiation Therapy Oncology Group protocol 91-06
24. Randomized study of chemotherapy radiation therapy combinations for favorable patients with locally advanced inoperable nonsmall cell lung cancer: Radiation Therapy Oncology Group (RTOG) 92-04
25. Randomized phase m trial of radiation ± amifostine in patients with head and neck cancer
26. Prophylactic cranial irradiation for patients with small cell lung cancer in complete remission